These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31820561)

  • 1. Two effects of GATA2 enhancer repositioning by 3q chromosomal rearrangements.
    Suzuki M; Katayama S; Yamamoto M
    IUBMB Life; 2020 Jan; 72(1):159-169. PubMed ID: 31820561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chromosomal rearrangements between 3q21 and 3q26 induce leukemogenesis by misdirecting both EVI1 and GATA2 genes].
    Suzuki M
    Rinsho Ketsueki; 2017; 58(7):806-812. PubMed ID: 28781278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
    Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.
    Yamaoka A; Suzuki M; Katayama S; Orihara D; Engel JD; Yamamoto M
    Blood Adv; 2020 Apr; 4(8):1722-1736. PubMed ID: 32330245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.
    Yamazaki H; Suzuki M; Otsuki A; Shimizu R; Bresnick EH; Engel JD; Yamamoto M
    Cancer Cell; 2014 Apr; 25(4):415-27. PubMed ID: 24703906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
    Gröschel S; Sanders MA; Hoogenboezem R; de Wit E; Bouwman BAM; Erpelinck C; van der Velden VHJ; Havermans M; Avellino R; van Lom K; Rombouts EJ; van Duin M; Döhner K; Beverloo HB; Bradner JE; Döhner H; Löwenberg B; Valk PJM; Bindels EMJ; de Laat W; Delwel R
    Cell; 2014 Apr; 157(2):369-381. PubMed ID: 24703711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
    Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
    Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
    Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
    Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.
    Smeenk L; Ottema S; Mulet-Lazaro R; Ebert A; Havermans M; Varea AA; Fellner M; Pastoors D; van Herk S; Erpelinck-Verschueren C; Grob T; Hoogenboezem RM; Kavelaars FG; Matson DR; Bresnick EH; Bindels EM; Kentsis A; Zuber J; Delwel R
    Cancer Discov; 2021 Nov; 11(11):2868-2883. PubMed ID: 33980539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
    Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
    Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities.
    Baldazzi C; Luatti S; Zuffa E; Papayannidis C; Ottaviani E; Marzocchi G; Ameli G; Bardi MA; Bonaldi L; Paolini R; Gurrieri C; Rigolin GM; Cuneo A; Martinelli G; Cavo M; Testoni N
    Genes Chromosomes Cancer; 2016 Apr; 55(4):375-88. PubMed ID: 26815134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts.
    Martinelli G; Ottaviani E; Buonamici S; Isidori A; Borsaru G; Visani G; Piccaluga PP; Malagola M; Testoni N; Rondoni M; Nucifora G; Tura S; Baccarani M
    Haematologica; 2003 Nov; 88(11):1221-8. PubMed ID: 14607750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review.
    De Braekeleer M; Le Bris MJ; De Braekeleer E; Basinko A; Morel F; Douet-Guilbert N
    Future Oncol; 2015; 11(11):1675-86. PubMed ID: 26043219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
    Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26).
    Suzukawa K; Parganas E; Gajjar A; Abe T; Takahashi S; Tani K; Asano S; Asou H; Kamada N; Yokota J
    Blood; 1994 Oct; 84(8):2681-8. PubMed ID: 7919381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
    Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
    Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a dual-color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia.
    Shearer BM; Sukov WR; Flynn HC; Knudson RA; Ketterling RP
    Am J Hematol; 2010 Aug; 85(8):569-74. PubMed ID: 20556821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
    Ottema S; Mulet-Lazaro R; Erpelinck-Verschueren C; van Herk S; Havermans M; Arricibita Varea A; Vermeulen M; Beverloo HB; Gröschel S; Haferlach T; Haferlach C; J Wouters B; Bindels E; Smeenk L; Delwel R
    Nat Commun; 2021 Sep; 12(1):5679. PubMed ID: 34584081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.